An Open Label, Randomized, Single Dose, Crossover Study to Determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Heart failure; Pulmonary oedema
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 24 Jan 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.